<SEC-DOCUMENT>0001206774-15-003036.txt : 20150914
<SEC-HEADER>0001206774-15-003036.hdr.sgml : 20150914
<ACCEPTANCE-DATETIME>20150914171525
ACCESSION NUMBER:		0001206774-15-003036
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20150914
DATE AS OF CHANGE:		20150914

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-206659
		FILM NUMBER:		151106162

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>geron_424b5.htm
<DESCRIPTION>PROSPECTUS FILED PURSUANT TO RULE 424(B)(5)
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">
<BR>

<P STYLE="text-align: right"><FONT face="Times New Roman" size=2><STRONG>Filed Pursuant to Rule 424(b)5<BR>
Registration No. 333-206659</STRONG></FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>PROSPECTUS</FONT></B></P>
<P align=center><IMG src="geron_s33x10x1.jpg" border=0><BR><B><FONT face="Times New Roman">$50,000,000<BR>Common
Stock<BR>____________________</FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have entered into an at
market issuance sales agreement, or sales agreement, with MLV &amp; Co., LLC, or
MLV, relating to shares of our common stock offered by this prospectus. In
accordance with the terms of the sales agreement, we may offer and sell shares
of our common stock from time to time through MLV having an aggregate offering
price of up to $50.0 million.</font></p>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our common stock is listed on The NASDAQ Global
Select Market under the symbol &#147;GERN.&#148; On September 11, 2015, the last reported
sale price of our common stock on The NASDAQ Global Select Market was $3.53 per
share.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Sales of our common stock, if
any, under this prospectus may be made in sales deemed to be &#147;at the market
offerings&#148; as defined in Rule 415 promulgated under the Securities Act of 1933,
as amended, or the Securities Act, including sales made directly on or through
The NASDAQ Global Select Market, the existing trading market for our common
stock, sales made to or through a market maker other than on an exchange or
otherwise, in negotiated transactions at market prices prevailing at the time of
sale or at prices related to such prevailing market prices, and/or any other
method permitted by law. MLV will act as sales agent on a best efforts basis
using commercially reasonable efforts to sell on our behalf all of the shares of
common stock requested to be sold by us, consistent with its normal trading and
sales practices, on mutually agreed terms between MLV and us. There is no
arrangement for funds to be received in any escrow, trust or similar
arrangement.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The compensation to MLV for
sales of common stock sold pursuant to the sales agreement is an aggregate of up
to 3.0% of the gross proceeds of the sales price per share. In connection with
the sale of the common stock on our behalf, MLV will be deemed to be an
&#147;underwriter&#148; within the meaning of the Securities Act, and the compensation of
MLV will be deemed to be underwriting commissions or discounts. We have also
agreed to provide indemnification and contribution to MLV with respect to
certain liabilities, including liabilities under the Securities Act.</FONT></P>
<P align=center><B><FONT face="Times New Roman">____________________</FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><B><I><FONT face="Times New Roman" size=2>Investing in our common
stock involves a high degree of risk. Please read the information contained in
and incorporated by reference under the heading &#147;Risk Factors&#148; beginning on
page 4 of this prospectus, and under similar headings in the other documents
that are filed after the date hereof and incorporated by reference into this
prospectus.</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><B><FONT face="Times New Roman" size=2>Neither the Securities and
Exchange Commission nor any state securities commission has approved or
disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal
offense.</FONT></B></P>
<P align=center><B><FONT face="Times New Roman">____________________</FONT></B></P>
<P align=center><IMG src="geron_s33x10x2.jpg" border=0><BR><FONT face="Times New Roman" size=2>T</FONT><FONT face="Times New Roman" size=2>he
date of thi</FONT><FONT face="Times New Roman" size=2>s</FONT><FONT face="Times New Roman" size=2> prospectus is September 11, 2015.</FONT><FONT face="Times New Roman" size=2></FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=center><B><FONT face="Times New Roman" size=2>TABLE OF CONTENTS
</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="99%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Page</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>About This Prospectus</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%"><FONT face="Times New Roman" size=2>Prospectus Summary</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>2</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Risk Factors</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>4</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%"><FONT face="Times New Roman" size=2>Forward-Looking Statements</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>5</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Use of Proceeds</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>6</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%"><FONT face="Times New Roman" size=2>Dilution</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>7</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Description of Capital Stock</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>8</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%"><FONT face="Times New Roman" size=2>Plan
      of Distribution</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>10</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Legal Matters</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>11</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%"><FONT face="Times New Roman" size=2>Experts</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>11</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Where You Can Find More
Information</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>11</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="99%"><FONT face="Times New Roman" size=2>Incorporation of Certain Information by Reference</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>i </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=center><B><FONT face="Times New Roman" size=2>ABOUT THIS PROSPECTUS
</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This prospectus relates to the
offering of our common stock. Before buying any of the common stock that we are
offering, we urge you to carefully read this prospectus, together with the
information incorporated by reference as described under the heading
&#147;Incorporation of Certain Information by Reference&#148; in this prospectus. These
documents contain important information that you should consider when making
your investment decision.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This prospectus describes the
specific terms of the common stock we are offering and also adds to and updates
information contained in the documents incorporated by reference into this
prospectus. To the extent there is a conflict between the information contained
in this prospectus, on the one hand, and the information contained in any
document incorporated by reference into this prospectus that was filed with the
Securities and Exchange Commission, or SEC, before the date of this prospectus,
on the other hand, you should rely on the information in this prospectus. If any
statement in one of these documents is inconsistent with a statement in another
document having a later date &#151; for example, a document incorporated by reference
into this prospectus &#151; the statement in the document having the later date
modifies or supersedes the earlier statement.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 30pt"><FONT face="Times New Roman" size=2>You should rely only on the
information contained in, or incorporated by reference into this prospectus and
in any free writing prospectus that we may authorize for use in connection with
this offering. We have not, and MLV has not, authorized any other person to
provide you with different information. If anyone provides you with different or
inconsistent information, you should not rely on it. We are not, and MLV is not,
making an offer to sell or soliciting an offer to buy our securities in any
jurisdiction in which an offer or solicitation is not authorized or in which the
person making that offer or solicitation is not qualified to do so or to anyone
to whom it is unlawful to make an offer or solicitation. You should assume that
the information appearing in this prospectus, the documents incorporated by
reference into this prospectus, and in any free writing prospectus that we may
authorize for use in connection with this offering, is accurate only as of the
date of those respective documents. Our business, financial condition, results
of operations and prospects may have changed since those dates. You should read
this prospectus, the documents incorporated by reference into this prospectus,
and any free writing prospectus that we may authorize for use in connection with
this offering, in their entirety before making an investment decision. You
should also read and consider the information in the documents to which we have
referred you in the sections of this prospectus titled &#147;Where You Can Find More
Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148;</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>1 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR><div style="padding-top: 4pt; padding-bottom: 4pt; padding-left: 12pt; padding-right: 12pt; border: 1pt solid black">
<P align=center><B><FONT face="Times New Roman" size=2>PROSPECTUS SUMMARY
</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>This summary highlights
certain information about us, this offering and selected information contained
elsewhere in or incorporated by reference into this prospectus. This summary is
not complete and does not contain all of the information that you should
consider before deciding whether to invest in our common stock. For a more
complete understanding of our company and this offering, we encourage you to
read and consider carefully the more detailed information in this prospectus,
including the information incorporated by reference into this prospectus, and
the information included in any free writing prospectus that we have authorized
for use in connection with this offering, including the information contained in
and incorporated by reference under the heading &#147;Risk Factors&#148; beginning on page
4 of this prospectus, and under similar headings in the other documents that are
filed after the date hereof and incorporated by reference into this
prospectus.</FONT></I></P>
<P align=center><B><FONT face="Times New Roman" size=2>Geron Corporation
</FONT></B></P>
<P align=left><B><FONT face="Times New Roman" size=2>Overview </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Geron is a clinical stage
biopharmaceutical company focused on the development of a telomerase inhibitor,
imetelstat, in hematologic myeloid malignancies. The discovery and early
development of imetelstat, our sole product candidate, was based on our core
expertise in telomerase and telomere biology. Telomerase is an enzyme that
enables cancer cells, including malignant progenitor cells, to maintain telomere
length, which provides them with the capacity for limitless, uncontrolled
proliferation. Using our proprietary nucleic acid chemistry, we designed
imetelstat to be an oligonucleotide that targets and binds with high affinity to
the active site of telomerase, thereby directly inhibiting telomerase activity
and impeding malignant cell proliferation. Molecular responses in essential
thrombocythemia, or ET, and remission responses, including reversal of bone
marrow fibrosis, in myelofibrosis, or MF, suggest imetelstat has disease
modifying activity by inhibiting the progenitor cells of the malignant clone for
the underlying disease in a relatively selective manner. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>On November 13, 2014, we
entered into an exclusive collaboration and license agreement, or the
Collaboration Agreement, with Janssen Biotech, Inc., or Janssen, to develop and
commercialize imetelstat worldwide for all indications in oncology, including
hematologic myeloid malignancies, and all other human therapeutic uses. The
Collaboration Agreement became effective on December 15, 2014 and we received
$35 million from Janssen as an upfront payment. Additional consideration under
the Collaboration Agreement includes payments up to a potential total of $900
million for the achievement of development, regulatory and commercial
milestones, as well as royalties on worldwide net sales. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under the Collaboration
Agreement, Janssen is responsible for the development, manufacturing and
commercialization of, and seeking regulatory approval for imetelstat worldwide.
Development of imetelstat will proceed under a mutually agreed clinical
development plan, which includes two Phase 2 studies to be pursued initially,
one in MF, referred to as the Initial Phase 2 MF Study, and one in
myelodysplastic syndrome, or MDS, referred to as the Initial Phase 2 MDS Study.
Janssen opened the Initial Phase 2 MF Study, named the IMbark<SUP>TM</SUP>
Study, to enrollment in July 2015. We expect Janssen to initiate the Initial
Phase 2 MDS Study by the end of 2015. In addition, the clinical development plan
may also include additional, possible registration studies in MF and MDS, and
possible exploratory Phase 2 and potential follow on Phase 3 studies in acute
myelogenous leukemia. </FONT></P>


<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>On June 11, 2015, the United
States Food and Drug Administration, or FDA, granted orphan drug designation to
imetelstat for the treatment of MF. Orphan drug designation qualifies the
sponsor of the drug for various development incentives under the Orphan Drug
Act, or ODA, including, if regulatory approval is received, seven years of
market exclusivity with certain limited exceptions, exemption from FDA
application fees and certain tax credits for qualified clinical testing. The
granting of orphan drug designation does not alter the standard regulatory
requirements and process for obtaining marketing approval. The safety and
effectiveness of a drug must be established through adequate and well-controlled
studies. Orphan drug exclusivity does not prevent the FDA from approving a
different drug for the same disease or condition, or the same drug for a
different disease or condition. </FONT></P>


<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We are subject to risks common
to companies in our industry and at our stage of development, including but not
limited to risks related to our research and development efforts, our dependence
on Janssen or the development, regulatory approval, manufacture and
commercialization of our sole product candidate, imetelstat, need for future
capital, uncertainty of preclinical or clinical trial results or regulatory
approvals or clearances, the future development of imetelstat, including any
future efficacy or safety results that cause the benefit-risk profile of
imetelstat to become unacceptable, enforcement of our patent and proprietary
rights, reliance upon our collaborators, investigators, and other third parties,
potential competition and other risks. We do not expect to receive revenues or
royalties based on therapeutic products for a number of years, if at all.
</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Company Information
</FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We were incorporated in 1990
under the laws of Delaware. Our principal executive offices are located at 149
Commonwealth Drive, Suite 2070, Menlo Park, California 94025 and our telephone
number is (650) 473-7700. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>2 </FONT></P></div><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR><div style="padding-top: 4pt; padding-bottom: 4pt; padding-left: 12pt; padding-right: 12pt; border: 1pt solid black">
<P align=left><FONT face="Times New Roman" size=2>Our website address is
www.geron.com. Information found on, or accessible through, our website is not a
part of, and is not incorporated into, this prospectus, and you should not
consider it part of this prospectus. Our website address is included in this
document as an inactive textual reference only. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Unless the context indicates
otherwise, as used in this prospectus, the terms &#147;Geron,&#148; &#147;Geron Corporation,&#148;
&#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Geron Corporation, a Delaware corporation.
</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>The Offering
</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=left width="29%"><FONT face="Times New Roman" size=2>Common stock offered by us</FONT></TD>
    <TD vAlign=top align=left width="71%">
      <P align=left><FONT face="Times New Roman" size=2>In accordance with the
      terms of the sales agreement, we may offer and sell shares of our common
      stock from time to time through MLV having an aggregate offering price of
      up to $50.0 million. </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="29%"></TD>
    <TD vAlign=top align=left width="71%">&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap align=left width="29%">
      <P align=left><FONT face="Times New Roman" size=2>Manner of offering
      </FONT></P></TD>
    <TD vAlign=top align=left width="71%">
      <P align=left><FONT face="Times New Roman" size=2>&#147;At the market&#148; offering
      that may be made from time to time through MLV as our sales agent. See
      &#147;Plan of Distribution&#148; on page 10. </FONT></P></TD></TR></TABLE><BR>
<P align=left><B><I><FONT face="Times New Roman" size=2>Use of Proceeds
</FONT></I></B><I><FONT face="Times New Roman" size=2></FONT></I></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We currently intend to use the
net proceeds from this offering, if any, for working capital and general
corporate purposes, including but not limited to fund research and development
activities to support our imetelstat collaboration with Janssen and to fund
general and administrative activities. We may also use a portion of the net
proceeds from this offering to potentially in-license or acquire other oncology
products, programs or companies to diversify our business. See &#147;Use of Proceeds&#148;
on page 6 of this prospectus.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Risk Factors
</FONT></I></B><I><FONT face="Times New Roman" size=2></FONT></I></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Investing in our common stock
involves a high degree of risk. Please read the information contained in and
incorporated by reference under the heading &#147;Risk Factors&#148; beginning on page 4
of this prospectus, and under similar headings in the other documents that are
filed after the date hereof and incorporated by reference into this
prospectus.</FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>NASDAQ Global Select
Market Listing </FONT></I></B><I><FONT face="Times New Roman" size=2></FONT></I></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our common stock is listed on
The NASDAQ Global Select Market under the symbol &#147;GERN.&#148;</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>3</FONT><FONT face="Times New Roman" size=2> </FONT></P></div><br>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>RISK FACTORS
</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Investing in our common
stock involves a high degree of risk. Before deciding whether to invest in our
common stock, you should consider carefully the risks and uncertainties
described below and discussed under the section &#147;Risk Factors&#148; contained in our
Quarterly Report for the period ended June 30, 2015, which are incorporated by
reference into this prospectus in their entirety, as updated or superseded by
the risks and uncertainties described under similar headings in the other
documents that are filed after the date hereof and incorporated by reference
into this prospectus, together with other information in this prospectus, the
information and documents incorporated by reference and any free writing
prospectus that we may authorize for use in connection with this offering. The
risks described in these documents are not the only ones we face, but those that
we consider to be material. There may be other unknown or unpredictable
economic, business, competitive, regulatory or other factors that could have
material adverse effects on our future results. Past financial performance may
not be a reliable indicator of future performance, and historical trends should
not be used to anticipate results or trends in future periods. If any of these
risks actually occurs, our business, financial condition, results of operations
or cash flow could be seriously harmed. This could cause the trading price of
our common stock to decline, resulting in a loss of all or part of your
investment. Please also read carefully the section below titled &#147;Forward-Looking
Statements.&#148;</FONT></I></P>
<P align=left><B><FONT face="Times New Roman" size=2>Additional Risks Related to
This Offering </FONT></B></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>Management will have
broad discretion as to the use of the proceeds from this offering and may not
use the proceeds effectively.</FONT></I></B><FONT face="Times New Roman" size=2>
</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Because we have not designated
the amount of net proceeds from this offering to be used for any particular
purpose, our management will have broad discretion as to the application of the
net proceeds from this offering and could use them for purposes other than those
contemplated at the time of the offering. Our management may use the net
proceeds for corporate purposes that may not improve our financial condition or
market value. </FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>You may experience
immediate and substantial dilution.</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The offering prices per share
in this offering may exceed the net tangible book value per share of our common
stock. Assuming that an aggregate of 16,233,766 shares of our common stock are
sold at a price of $3.08 per share pursuant to this prospectus, which was the
last reported sale price of our common stock on The NASDAQ Global Select Market
on August 21, 2015, for aggregate gross proceeds of $50.0 million, after
deducting commissions and estimated aggregate offering expenses payable by us,
you would experience immediate dilution of $2.12 per share, representing the
difference between our as adjusted net tangible book value per share as of June
30, 2015 after giving effect to this offering and the assumed offering price.
The exercise of outstanding stock options and warrants may result in further
dilution of your investment. See the section titled &#147;Dilution&#148; below for a more
detailed illustration of the dilution you would incur if you participate in this
offering. </FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>You may experience
future dilution as a result of future equity offerings.</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In order to raise additional
capital, we may in the future offer additional shares of our common stock or
other securities convertible into or exchangeable for our common stock at prices
that may not be the same as the price per share paid by any investor in this
offering. We may sell shares or other securities in any other offering at a
price per share that is less than the price per share paid by any investor in
this offering, and investors purchasing shares or other securities in the future
could have rights superior to you. The price per share at which we sell
additional shares of our common stock, or securities convertible or exchangeable
into common stock, in future transactions may be higher or lower than the price
per share paid by any investor in this offering. </FONT></P>
<P align=left><B><I><FONT face="Times New Roman" size=2>We do not intend to pay
dividends in the foreseeable future.</FONT></I></B><FONT face="Times New Roman" size=2> </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have never paid cash
dividends on our common stock and currently do not plan to pay any cash
dividends in the foreseeable future. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>4 </FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>FORWARD-LOOKING
STATEMENTS </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This prospectus, the documents
we have filed with the SEC that are incorporated by reference and any free
writing prospectuses that we may authorize for use in connection with this
offering contain &#147;forward-looking statements&#148; within the meaning of Section 27A
of the Securities Act of 1933, as amended, or the Securities Act, and Section
21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.
These statements relate to future events or to our future operating or financial
performance and involve known and unknown risks, uncertainties and other factors
which may cause our actual results, performance or achievements to be materially
different from any future results, performances or achievements expressed or
implied by the forward-looking statements. Forward-looking statements may
include, but are not limited to, statements about:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>changes or delays in our and Janssen&#146;s
      development plans for imetelstat, including changes which may result from
      any future clinical holds on the investigational new drug applications for
      imetelstat; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>the progress, timing, magnitude, scope and
      costs of clinical development, manufacturing and commercialization for
      imetelstat, including the number of indications being pursued, subject to
      permission from the FDA and other regulatory agencies; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>Janssen&#146;s ability to consistently and
      reproducibly manufacture imetelstat; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>the time and costs involved in obtaining
      regulatory clearances and approvals in the United States and in other
      countries; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>Janssen&#146;s ability to successfully market and
      sell imetelstat, upon any regulatory approval or clearance, in the United
      States and other countries; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>the achievement of development, regulatory
      and commercial milestones resulting in the payment to us from Janssen
      under the Collaboration Agreement and the timing of receipt or recognition
      of such payments, if any; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>the timing, receipt and amount of royalties
      under the Collaboration Agreement on worldwide net sales of imetelstat,
      upon regulatory approval or clearance, if any;</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>the implementation of our corporate
      strategy, including our ability to in-license or acquire any new product
      candidates, programs or companies to diversify our business;
  </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>our ability to protect our intellectual
      property and operate our business without infringing upon the intellectual
      property rights of others; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>the size and timing of expenditures and
      whether there are unanticipated expenditures; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>our requirements for additional capital;
      </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>our estimates regarding the sufficiency of
      our cash resources and our use of the net proceeds from this offering; and
      </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>our future financial
    performance.</FONT></P></TD></TR></TABLE>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In some cases, you can
identify forward-looking statements by terms such as &#147;may,&#148; &#147;plan,&#148; &#147;intend,&#148;
&#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;predicts,&#148; &#147;potential&#148; and similar
expressions intended to identify forward-looking statements. These statements
reflect our current views with respect to future events, are based on
assumptions and are subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements. We discuss in greater detail, and incorporate by reference into this
prospectus in their entirety, many of these risks and uncertainties under the
headings &#147;Risk Factors&#148; on page 4 of this prospectus and in our Quarterly Report
on Form 10-Q for the quarter ended June 30, 2015, which is incorporated herein
by reference, as may be updated or</FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>5</FONT><FONT face="Times New Roman" size=2>
</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>


<P ALIGN="LEFT" ><FONT face="Times New Roman" size=2>superseded by the risks and uncertainties
described under similar headings in the other documents that are filed after the
date hereof and incorporated by reference into this prospectus. Also, these
forward-looking statements represent our estimates and assumptions only as of
the date of the document containing the applicable statement. Unless required by
law, we undertake no obligation to update or revise any forward-looking
statements to reflect new information or future events or developments. Thus,
you should not assume that our silence over time means that actual events are
bearing out as expressed or implied in such forward-looking statements. You
should read this prospectus together with the documents we have filed with the
SEC that are incorporated by reference and any free writing prospectus that we
may authorize for use in connection with this offering completely and with the
understanding that our actual future results may be materially different from
what we expect. We qualify all of the forward-looking statements in the
foregoing documents by these cautionary statements.</FONT></P>



<P STYLE="text-align: center"><B><FONT face="Times New Roman" size=2>USE OF
PROCEEDS</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We currently intend to use the
net proceeds from this offering, if any, for working capital and general
corporate purposes, including but not limited to fund research and development
activities to support our imetelstat collaboration with Janssen and to fund
general and administrative activities. We may also use a portion of the net
proceeds from this offering to potentially in-license or acquire other oncology
products, programs or companies to diversify our business.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The amounts and timing of our
use of the net proceeds from this offering, if any, will depend on a number of
factors, such as the timing and progress of the imetelstat development program
under the Collaboration Agreement with Janssen, the timing and progress of any
potential acquisition or in-licensing efforts and the availability and cost of
other capital. As of the date of this prospectus, we cannot specify with
certainty all of the particular uses for the net proceeds to us from this
offering. Accordingly, our management will have broad discretion in the timing
and application of these proceeds. Pending application of the net proceeds as
described above, we intend to temporarily invest the proceeds in short-term,
interest-bearing instruments.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>6</FONT><FONT face="Times New Roman" size=2>
</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>DILUTION</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you invest in this
offering, your ownership interest will be diluted to the extent of the
difference between the public offering price per share and the as adjusted net
tangible book value per share after giving effect to this offering. We calculate
net tangible book value per share by dividing the net tangible book value, which
is tangible assets less total liabilities, by the number of outstanding shares
of our common stock. Dilution represents the difference between the portion of
the amount per share paid by purchasers of shares in this offering and the as
adjusted net tangible book value per share of our common stock immediately after
giving effect to this offering. Our net tangible book value as of June 30, 2015
was approximately $118.4 million, or $0.75 per share.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>After giving effect to the
sale of our common stock during the term of the sales agreement with MLV in the
aggregate amount of $50,000,000 at an assumed offering price of $3.08 per share,
the last reported sale price of our common stock on The NASDAQ Global Select
Market on August 21, 2015, and after deducting commissions and estimated
aggregate offering expenses payable by us, our net tangible book value as of
June 30, 2015 would have been $167.0 million, or $0.96 per share of common
stock. This represents an immediate increase in the net tangible book value of
$0.21 per share to our existing stockholders and an immediate dilution in net
tangible book value of $2.12 per share to new investors. The following table
illustrates this per share dilution:</FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Assumed public offering price per
      share</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>3.08</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net tangible book value per
      share as of June 30, 2015</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>0.75</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      Increase in net tangible book value per share attributable to this
      offering</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0  ><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>0.21</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%"><FONT face="Times New Roman" size=2>As
      adjusted net tangible book value per share as of June 30, 2015,
      after</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; giving effect to this
      offering</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"  style="padding-bottom: .5pt"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>0.96</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Dilution per share to new investors
      purchasing shares in this offering</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0 style="padding-bottom: 1.5pt"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>2.12</FONT></TD></TR></TABLE></DIV><BR>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The table above assumes for
illustrative purposes that an aggregate of 16,233,766 shares of our common stock
are sold during the term of the sales agreement with MLV at a price of $3.08 per
share, the last reported sale price of our common stock on The NASDAQ Global
Select Market on August 21, 2015, for aggregate gross proceeds of $50,000,000.
The shares subject to the sales agreement with MLV are being sold from time to
time at various prices. An increase of $0.50 per share in the price at which the
shares are sold from the assumed offering price of $3.08 per share shown in the
table above, assuming all of our common stock in the aggregate amount of
$50,000,000 during the term of the sales agreement with MLV is sold at that
price, would increase our adjusted net tangible book value per share after the
offering to $0.97 per share and would increase the dilution in net tangible book
value per share to new investors in this offering to $2.61 per share, after
deducting commissions and estimated aggregate offering expenses payable by us. A
decrease of $0.50 per share in the price at which the shares are sold from the
assumed offering price of $3.08 per share shown in the table above, assuming all
of our common stock in the aggregate amount of $50,000,000 during the term of
the sales agreement with MLV is sold at that price, would decrease our adjusted
net tangible book value per share after the offering to $0.94 per share and
would decrease the dilution in net tangible book value per share to new
investors in this offering to $1.64 per share, after deducting commissions and
estimated aggregate offering expenses payable by us. This information is
supplied for illustrative purposes only.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The above discussion and table
are based on 158,122,877 shares of our common stock issued and outstanding as of
June 30, 2015 and exclude the following, all as of June 30, 2015:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>18,249,993 shares of common stock issuable
      upon the exercise of outstanding stock options with a weighted-average
      exercise price of $3.29 per share; </FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>537,893 shares of common stock issuable upon
      the exercise of an outstanding warrant with an exercise price of $3.98 per
      share; and</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>up to an aggregate of 12,611,453 shares of
      common stock reserved for future issuance under our 2011 Incentive Award
      Plan and 2014 Employee Stock Purchase Plan.</FONT></P></TD></TR></TABLE>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The number of shares of our
common stock outstanding in the computations above includes 500 unvested </FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>7</FONT><FONT face="Times New Roman" size=2>
</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>



<P align=left><FONT face="Times New Roman" size=2>shares
of common stock issued as restricted stock awards and outstanding as of June 30,
2015.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>To the extent that options or
warrants outstanding as of June 30, 2015 have been or are exercised, or other
shares are issued, investors purchasing shares in this offering could experience
further dilution. In addition, we may choose to raise additional capital due to
market conditions or strategic considerations, including for potential
acquisition or in-licensing opportunities, even if we believe we have sufficient
funds for our current or future operating plans. To the extent that additional
capital is raised through the sale of equity or convertible debt securities, the
issuance of these securities could result in further dilution to our
stockholders.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>DESCRIPTION OF CAPITAL
STOCK </FONT></B></P>
<P align=left><B><FONT face="Times New Roman" size=2>General </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As of the date of this
prospectus, our restated certificate of incorporation, as amended, or the
Restated Certificate, authorizes us to issue 300,000,000 shares of common stock,
par value $0.001 per share, and 3,000,000 shares of preferred stock, par value
$0.001 per share. As of June 30, 2015, 158,122,877 shares of common stock were
outstanding and no shares of preferred stock were outstanding.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following summary
description of our capital stock is based on the provisions of our Restated
Certificate, our amended and restated bylaws, or the Bylaws, and applicable
provisions of the Delaware General Corporation Law. This information may not be
complete in all respects and is qualified entirely by reference to the
applicable provisions of our Restated Certificate, our Bylaws and the Delaware
General Corporation Law. For information on how to obtain copies of our Restated
Certificate and Bylaws, which are exhibits to the registration statement of
which this prospectus is a part, see "Where You Can Find More
Information."</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Common Stock
</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The holders of common stock
are entitled to one vote for each share held of record on all matters submitted
to a vote of the stockholders. Subject to preferences that may be applicable to
any outstanding shares of the preferred stock, the holders of common stock are
entitled to receive ratably such dividends as may be declared by the board of
directors out of legally available funds. Upon our liquidation, dissolution or
winding up, holders of our common stock are entitled to share ratably in all
assets remaining after payment of liabilities and the liquidation preferences of
any outstanding shares of preferred stock legally available for distribution to
stockholders. Holders of common stock have no preemptive rights and no right to
convert their common stock into any other securities. There are no redemption or
sinking fund provisions applicable to the common stock. When we issue shares of
common stock under this prospectus, the shares will be fully paid and
non-assessable.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Additional shares of
authorized common stock may be issued, as authorized by our board of directors
from time to time, without stockholder approval, except as may be required by
applicable stock exchange requirements.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Preferred Stock
</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Pursuant to our Restated
Certificate, our board of directors has the authority, without further action by
our stockholders, to issue up to 3,000,000 shares of preferred stock in one or
more series and to fix the designations, powers, preferences, privileges and
relative participating, optional or special rights and the qualifications,
limitations or restrictions thereof, including dividend rights, conversion
rights, voting rights, terms of redemption and liquidation preferences, any or
all of which may be greater than the rights of the common stock. The board of
directors, without stockholder approval, can issue preferred stock with voting,
conversion or other rights that could adversely affect the voting power and
other rights of the holders of common stock. Preferred stock could thus be
issued quickly with terms calculated to delay or prevent a change in control of
our company or make removal of management more difficult. Additionally, the
issuance of preferred stock may have the effect of decreasing the market price
of the common stock and may adversely affect the voting power of holders of
common stock and reduce the likelihood that common stockholders will receive
dividend payments and payments upon liquidation.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>8</FONT><FONT face="Times New Roman" size=2>
</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><B><FONT face="Times New Roman" size=2>Anti-takeover Effects of
Provisions of Charter Documents and Delaware Law </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Charter Documents.
</FONT></I><FONT face="Times New Roman" size=2>Our Restated Certificate and
Bylaws contain provisions that could discourage potential takeover attempts and
make it more difficult for stockholders to change management, which could
adversely affect the market place of our common stock.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Restated Certificate
limits the personal liability for monetary damages for breach of fiduciary duty
of our directors to Geron and our stockholders to the fullest extent permitted
by the Delaware General Corporation Law. The inclusion of this provision in our
Restated Certificate may reduce the likelihood of derivative litigation against
directors and may discourage or deter stockholders or management from bringing a
lawsuit against directors for breach of their fiduciary duty.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Restated Certificate
provides that all stockholder action must be effected at a meeting of
stockholders and not by a consent in writing. In addition, our Bylaws provide
that special meetings of stockholders may only be called by the board of
directors pursuant to a resolution adopted by a majority of the total number of
authorized directors, the chairman of the board of directors, the chief
executive officer or president (in the absence of a chief executive officer), or
at the request in writing of stockholders owning a majority of the amount of our
entire capital stock issued and outstanding and entitled to vote. Finally, our
Bylaws establish procedures, including advance notice procedures, with regard to
the nomination of candidates for election as directors and stockholder
proposals.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Bylaws provides for the
board of directors to be divided into three classes of directors, with each
class as nearly equal in number as possible, serving staggered three-year terms.
As a result, approximately one-third of the board of directors will be elected
each year. The classified board provision could have the effect of discouraging
a third party from making a tender offer or attempting to obtain control of us.
In addition, the classified board provision could delay stockholders who do not
agree with the policies of the board of directors from removing a majority of
the board of directors for two years.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Delaware Law.
</FONT></I><FONT face="Times New Roman" size=2>We are subject to Section 203 of
the Delaware General Corporation Law. Section 203 generally prohibits a public
Delaware corporation such as us from engaging in a "business combination" with
an "interested stockholder" for a period of three years following the time that
the stockholder became an interested stockholder, unless: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>prior to the time the stockholder became an
      interested stockholder, the board of directors of the corporation approved
      either the business combination or the transaction which resulted in the
      stockholder becoming an interested stockholder;</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>upon consummation of the transaction which
      resulted in the stockholder becoming an interested stockholder, the
      interested stockholder owned at least 85% of the voting stock of the
      corporation outstanding at the time the transaction commenced, excluding
      for purposes of determining the number of shares outstanding (a) shares
      owned by persons who are directors and also officers and (b) employee
      stock plans in which employee participants do not have the right to
      determine confidentially whether shares held subject to the plan will be
      tendered in a tender or exchange offer; or</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>at or subsequent to the time the stockholder
      became an interested stockholder, the business combination is approved by
      the board and authorized at an annual or special meeting of stockholders,
      and not by written consent, by the affirmative vote of at least
      66&#8532;% of the outstanding voting stock which is not owned by
      the interested stockholder.</FONT></P></TD></TR></TABLE>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Section 203 defines a business
combination to include: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: left" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>any merger or consolidation involving the
      corporation and the interested stockholder;</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="99%">&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>any sale, lease, exchange, mortgage, pledge,
      transfer or other disposition (in one transaction or a series of
      transactions) involving the interested stockholder of 10% or more of the
      assets of the corporation (or its majority-owned
  subsidiary);</FONT></P></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2></FONT><FONT face="Times New Roman" size=2>9</FONT><FONT face="Times New Roman" size=2>
</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>


<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>subject to exceptions,
      any transaction that results in the issuance or transfer by the
      corporation of any stock of the corporation to the interested
      stockholder;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>subject to exceptions,
      any transaction involving the corporation that has the effect, directly or
      indirectly, of increasing the proportionate share of the stock or any
      class or series of the corporation beneficially owned by the interested
      stockholder; and<BR></FONT>&nbsp;</P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>the receipt by the
      interested stockholder of the benefit, directly or indirectly (except
      proportionately as a stockholder of such corporation), of any loans,
      advances, guarantees, pledges or other financial benefits, other than
      certain benefits set forth in Section 203, provided by or through the
      corporation.</FONT></P></TD></TR></TABLE>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In general, Section 203
defines an interested stockholder as any entity or person beneficially owning
15% or more of the outstanding voting stock of the corporation and any entity or
person that is an affiliate or associate of such entity or person.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Although Section 203 permits
us to elect not to be governed by its provisions, we have not made this
election. As a result of the application of Section 203, potential acquirers of
Geron may be discouraged from attempting to effect an acquisition transaction
with us, thereby possibly depriving holders of our securities of certain
opportunities to sell or otherwise dispose of such securities at above-market
prices pursuant to such transactions.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Transfer Agent and
Registrar </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The transfer agent and
registrar for the common stock is Computershare, Inc. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Listing on The NASDAQ
Global Select Market </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our common stock is listed on
The NASDAQ Global Select Market under the symbol &#147;GERN.&#148;</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>PLAN OF DISTRIBUTION
</FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have entered into an at
market issuance sales agreement, or sales agreement, with MLV &amp; Co. LLC, or
MLV, under which we may issue and sell shares of our common stock having
aggregate sales proceeds of up to $50.0 million from time to time through MLV
acting as agent. MLV may sell the common stock by any method that is deemed to
be an &#147;at the market offering&#148; as defined in Rule 415 promulgated under the
Securities Act, including sales made directly on or through The NASDAQ Global
Select Market or any other existing trading market for the common stock in the
United States or to or through a market maker. MLV may also sell the common
stock in negotiated transactions, subject to our prior approval. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Each time we wish to issue and
sell common stock under the sales agreement, we will notify MLV of the number of
shares to be issued, the dates on which such sales are anticipated to be made
and any minimum price below which sales may not be made. Once we have so
instructed MLV, unless MLV declines to accept the terms of such notice, MLV has
agreed to use its commercially reasonable efforts consistent with its normal
trading and sales practices to sell such shares up to the amount specified on
such terms. The obligations of MLV under the sales agreement to sell our common
stock are subject to a number of conditions that we must meet. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The settlement between us and
MLV is generally anticipated to occur on the third trading day following the
date on which the sale was made. Sales of our common stock as contemplated in
this prospectus will be settled through the facilities of The Depository Trust
Company or by such other means as we and MLV may agree upon. There is no
arrangement for funds to be received in an escrow, trust or similar arrangement.
</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We will pay MLV a commission
equal to an aggregate of up to 3.0% of the gross proceeds we receive from the
sales of our common stock. We also agreed to reimburse MLV for legal expenses
incurred by it up to $20,000 in the aggregate. Because there is no minimum
offering amount required as a condition to close this offering, the actual total
public offering amount, commissions and proceeds to us, if any, are not
determinable at this time. In connection with the sale of the common stock on
our behalf, MLV will be deemed to be an &#147;underwriter&#148; within the
meaning of the Securities Act, and the compensation of MLV
will be deemed to be </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>10</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2>underwriting
commissions or discounts. We have agreed to provide indemnification and
contribution to MLV with respect to certain civil liabilities, including
liabilities under the Securities Act. We estimate that the total expenses for
the offering, excluding compensation payable to MLV under the terms of the sales
agreement, will be approximately $200,000. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The offering of our common
stock pursuant to the sales agreement will terminate upon the earlier of (i) the
sale of all of our common stock provided for in this prospectus, (ii) August 28, 2018, or (iii)
termination of the sales agreement as permitted therein. MLV may terminate the
sales agreement at any time in certain circumstances, including the occurrence
of a material adverse change with respect to us that, in MLV&#146;s sole judgment,
makes it impracticable or inadvisable to market the shares, if there has
occurred any material adverse change in the U.S. financial markets or
international financial markets, or any outbreak of hostilities or escalation
thereof or other calamity or crisis or any change or development involving a
prospective change in national or international political, financial or economic
conditions, which in MLV&#146;s sole judgment makes it impracticable or inadvisable
to market the shares, if trading in the shares has been suspended or limited by
the Securities Exchange Commission or The NASDAQ Global Select Market, or the
Exchange, or if trading generally has been suspended or limited by Exchange, if
any suspension of trading of any shares of the Company on any exchange or
over-the-counter market shall have occurred and be continuing, if there is a
major disruption of securities settlements or clearance services in the U.S.
which shall be continuing, or if a banking moratorium has been declared in the
U.S. Federal or New York authorities. We and MLV may each terminate the sales
agreement at any time upon ten days prior notice. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This summary of the material
provisions of the sales agreement does not purport to be a complete statement of
its terms and conditions. A copy of the sales agreement is filed with the SEC
and is incorporated by reference<SUP> </SUP>into the registration statement of
which this prospectus is a part. See &#147;Where You Can Find More Information&#148;
below. </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>To the extent required by
Regulation M under the Exchange Act, MLV will not engage in any market making
activities involving our common stock while the offering is ongoing under this
prospectus. </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>LEGAL
MATTERS</FONT></B><FONT face="Times New Roman" size=2> </FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Cooley LLP, San Francisco,
California, has passed upon the validity of the common stock offered by this
prospectus. LeClairRyan, A Professional Corporation, New York, New York, is
counsel for MLV in connection with this offering.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>EXPERTS </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The consolidated financial
statements of Geron Corporation appearing in Geron&#146;s Annual Report on Form 10-K
for the year ended December 31, 2014, and the effectiveness of internal control
over financial reporting as of December 31, 2014 have been audited by Ernst
&amp; Young LLP, independent registered public accounting firm, as set forth in
their reports thereon, included therein, and incorporated herein by reference.
Such consolidated financial statements are incorporated herein by reference in
reliance upon such reports given on the authority of such firm as experts in
accounting and auditing.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>WHERE YOU CAN FIND MORE
INFORMATION </FONT></B><FONT face="Times New Roman" size=2></FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This prospectus is part of the
registration statement on Form S-3 we filed with the SEC under the Securities
Act and does not contain all the information set forth in the registration
statement. Whenever a reference is made in this prospectus to any of our
contracts, agreements or other documents, the reference may not be complete and
you should refer to the exhibits that are a part of the registration statement
or the exhibits to the reports or other documents incorporated by reference into
this prospectus for a copy of such contract, agreement or other document.
Because we are subject to the information and reporting requirements of the
Exchange Act, we file annual, quarterly and current reports, proxy statements
and other information with the SEC. Our SEC filings are available to the public
over the Internet at the SEC&#146;s website at http://www.sec.gov. You may also read
and copy any document we file at the SEC&#146;s Public Reference Room at 100 F
Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for
further information on the operation of the Public Reference Room.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>11</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman" size=2>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE </FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The SEC allows us to
&#147;incorporate by reference&#148; information from other documents that we file with
it, which means that we can disclose important information to you by referring
you to those documents. The information incorporated by reference is considered
to be part of this prospectus. Information in this prospectus supersedes
information incorporated by reference that we filed with the SEC prior to the
date of this prospectus, while information that we file later with the SEC will
automatically update and supersede the information in this prospectus. We
incorporate by reference into this prospectus and the registration statement of
which this prospectus is a part the information or documents listed below that
we have filed with the SEC (Commission File No. 000-20859):</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>Geron&#146;s Annual Report on
      Form 10-K for the year ended December 31, 2014, filed with the SEC on
      March 11, 2015; <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>Geron&#146;s Quarterly
      Reports on Form 10-Q for the quarterly periods ended March 31, 2015 and
      June 30, 2015, filed with the SEC on May 7, 2015 and August 5, 2015,
      respectively;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>Geron&#146;s Current Reports
      on Form 8-K filed with the SEC on March 3, 2015 (other than the
      information furnished under Item 2.02 and the related exhibit), May 22,
      2015 and August 28, 2015; <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>the information
      specifically incorporated by reference into Geron&#146;s 2014 Annual Report on
      Form 10-K referred to above from Geron&#146;s revised definitive proxy
      statement relating to Geron&#146;s 2015 annual meeting of stockholders, filed
      with the SEC on April 3, 2015; and <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=left><FONT face="Times New Roman" size=2>the description of
      Geron&#146;s common stock set forth in Geron&#146;s registration statement on Form
      8-A, filed with the SEC on June 13, 1996. </FONT></P></TD></TR></TABLE>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We also incorporate by
reference any future filings (other than current reports furnished under Item
2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related
to such items unless such Form 8-K expressly provides to the contrary) made with
the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,
including those made after the date of the initial filing of the registration
statement of which this prospectus is a part and prior to effectiveness of such
registration statement, until the termination of the offering of the common
stock covered by this prospectus and will become a part of this prospectus from
the date that such documents are filed with the SEC. Information in such future
filings updates and supplements the information provided in this prospectus. Any
statements in any such future filings will automatically be deemed to modify and
supersede any information in any document we previously filed with the SEC that
is incorporated or deemed to be incorporated herein by reference to the extent
that statements in the later filed document modify or replace such earlier
statements.</FONT></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We will furnish without charge
to you, on written or oral request, a copy of any or all of the documents
incorporated by reference, including exhibits to these documents. You should
direct any requests for documents to Stephen Rosenfield, General Counsel and
Corporate Secretary, Geron Corporation, 149 Commonwealth Drive, Suite 2070,
Menlo Park, California 94025, telephone: (650) 473-7700.</FONT><B><FONT face="Times New Roman" size=2> </FONT></B></P>
<P align=center><FONT face="Times New Roman" size=2>12</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<BR><BR><BR><BR><BR>
<P align=center><FONT face="Times New Roman" size=6><b>$50,000,000</b></FONT></P>

<P align=center><FONT face="Times New Roman" size=6><b>Common Stock</b></FONT></P>

<P align=center><IMG src="geron_logo.jpg" border=0></p>

<P align=center><FONT face="Times New Roman" size=2>_______________________________<BR>
<BR><b><font size=6>Prospectus</font></b><BR>_______________________________</FONT></P><br>

<P align=center><IMG src="geron_s33x10x2.jpg" border=0></p>

<P align=center><FONT face="Times New Roman" size=2><b>September 11, 2015</b></FONT></P>
<BR><BR><BR><BR><BR>

<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>geron_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !? +(# 2(  A$! Q$!_\0
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M4/CWP;XKO?B9>6.JSW"1H=3\.+H^CW2Z1'&6GN;VTN)[BWV;H[:5RH/\U_\
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MUT72+J'2H8G,]Q>V[W4H16 MY2"M?V-?"'XP?"WX_?#7PW\8?@I\1/#?Q/\
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MM'<:GKW@+1-<U[5;A8403ZCK.M:C?:IJ-Y)F:[O+N>XF=WD;/^9U_P '7?\
MRF@^.W_9/?@M_P"H#IU?Z?\ ^P!_R8K^QI_V:U\ _P#U5OA:@#ZV9 RE>@.>
M@'5CDGD=<Y/XGO@C^#G_ (/@2R_#G]@*/<^T^-/C:S+N(C9UT/P.-YC^[O\
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M /\ ,_\ ^#UC_D_;]F7_ +-@7_U8GBBO[@?^")O_ "B6_P""??\ V;'\-_\
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MA<:W<&TT@^(?%'PJET?2AJETL<QMK%KR\@%Q.(9/+0,VQCA3_"]'_P &=O\
MP5I:-&DNOV:XY&53)&/BU<R!'(!9!(/#"APK$J&PN[ .T9P #ZF_X,F?^3R_
MVN/^S?/#/_J=+7^E "#R""/;\OZ&OXZO^#<+_@AO^VQ_P2O_ &C/CS\3?VEY
M/A+-X5^(WPDT?P=X?;P%XUG\2ZD=;L?$PU:5+RTDT?3UM;,6JG_2/,E+R[45
M %)/]B48VA0%(^0=>W).WUR-QH _R2_^#KO_ )30?';_ +)[\%O_ % =.K_3
M_P#V /\ DQ7]C3_LUKX!_P#JK?"U?Y@'_!UW_P IH/CM_P!D]^"W_J Z=7^G
M_P#L ?\ )BO[&G_9K7P#_P#56^%J /KFOX-O^#X/_DGG[ 7_ &.?QN_],?@6
MO[R:_@V_X/@_^2>?L!?]CG\;O_3'X%H _0/_ (,VO^43OBG_ +.P^*__ *B?
MPTK^HKXI_P#),/B/_P!B'XO_ /4>U&OY=?\ @S:_Y1.^*?\ L[#XK_\ J)_#
M2OZBOBG_ ,DP^(__ &(?B_\ ]1[4: /\>/\ X(-_\IMOV%/^SC+G_P!,/BVO
M]EBO\:?_ ((-_P#*;;]A3_LXRY_],/BVO]EB@#^%K_@^$_Y(;_P3_P#^RK_'
M/_U$/ %?>?\ P9X?\HG+G_LXCXH_^BM"KX,_X/A/^2&_\$__ /LJ_P <_P#U
M$/ %?>?_  9X?\HG+G_LXCXH_P#HK0J /Z0_VFO^3;_V@/\ LBGQ3_\ 4'UV
MO\;?_@CM_P I:OV$?^SJ_AU_ZD:U_LD?M-?\FW_M ?\ 9%/BG_Z@^NU_C;_\
M$=O^4M7["/\ V=7\.O\ U(UH _VL&ZGZG^=%#=3]3_.B@#_,^_X/5R&_;U_9
ME(.0?V7T/X'XB>)R#^.17]P7_!$S_E$M_P $^_\ LV/X<?\ IL-?Q*?\'K7A
MKQ#:?MI_LI>*KG2+^/PUJO[.-_HFFZ\T#G2[[6-$\=ZO<:OIT%VH,+7EC;ZG
MIT]Q!N600WD,@4H=P_KH_P"#=O\ :9^$7[0W_!)_]D[2OAKXRT/Q#XI^!WPO
MT#X0_%WPOI]XKZYX \;>&X[FW33?$&F2E+RT36=.@@UK1+QHVLM3T^Y,EG<2
MO;W45N ;_P#P<1?\H;?VXO\ LF-K_P"I/H=?R%_\&1__ ">I^V+_ -FNZ)_Z
MMCPM7]>?_!Q$?^--G[<)/&?AA:=>.3XGT/CGO[5_(9_P9'_\GJ?MB_\ 9KNB
M?^K8\+4 ?Z3U?Y"7_!T1_P IH_VI?^O+X7_^JZ\/U_KVU_D:_P#!U+X2\2>&
M/^"S'[0-]KVES:=:>,/"GPK\3^&IY)()$U?0)?!>G:5'J4'DRR,D1U+2=1LR
MDZQ3+-9R@QA=K, ?Z6W_  2._P"48?[!W3/_  R]\(\9]?\ A$[ _P!,_A7Z
M%Q Y+'GY,D8QE@Q*^WR@%5 ^[CG!K\K/^")/Q7^'OQ=_X)4?L/\ B#X<^*-,
M\5:/H?P+\%^!==N--F:1M$\:>!--M]"\5>&=4A,:RV>L:+K%G/9WUM.B$!8Y
MX6EMI[>:7Y@_X.8_VAM%^ /_  2$_:*ND^)NH_#7XA?$>^^'OP^^$MUX<U_4
M?#_B[7?&=UX\\/:]?:5X:O=(GMM222W\(Z)XDU;5YK>>"*+1-/OS--\T<,P!
M^^BH3E]I1\DC)ZL4 .1D@ G!P.XS]94R%7=C.!G&<9QVSD_J:_STO^#-7XG_
M +1OQB_::_:ZU[XF_%SXK_$SP=X:^#7@[3D7X@_$CQ;XQL=,\0ZOXLN'LGLM
M/\1ZOJ,,5W-96-TK7,"QR+$GEL6#C;_H61Y"*I4*54 @'*CCH">2 ,<D9H _
MR2O^#KO_ )30?';_ +)[\%O_ % =.K_3_P#V /\ DQ7]C3_LUKX!_P#JK?"U
M?Y@'_!UW_P IH/CM_P!D]^"W_J Z=7^G_P#L ?\ )BO[&G_9K7P#_P#56^%J
M /KFOX-O^#X/_DGG[ 7_ &.?QN_],?@6O[QF8@-A23MR !R2=W'/'89STR,U
M_"=_P>\^']8N/@Y^P?XGAT^]?1-,^(WQ?T?4+]+.ZDM+'4-5\.^%;JPMKJ^2
M)K.VDO(M,O39P3S1SW*VTS0)(L$QC /N[_@S:_Y1.^*?^SL/BO\ ^HG\-*_J
M*^*?_),/B/\ ]B'XO_\ 4>U&OY/?^#,SXD>!-7_X)J_%'X9Z3XMT2^^(O@C]
MIKQKX@\6>"(;V+_A)-#T'Q=X4\#IX8UN^TIF6[71=<ET?5[?3=6CB>PN+W2=
M2L$G-Y87<$7]0/[4OQ2\"?!;]F[X[?%;XG^(K+PG\/\ P%\)?'GB7Q9XAU"1
M8[?3=*L?#>H-(RHQ#W%U=2-'9Z=90YN;_4)K>RMDDN)XHW /\B3_ ((-_P#*
M;;]A3_LXRY_],/BVO]EBO\:K_@@+#=:[_P %KOV$;C2;&^O5;X\WNL/%;VSS
MSV^F0>%_%M]=7MRD(D$-O968>XO9V8PV\4<DCR;%S7^RH.@YSP.>F??':@#^
M%O\ X/A/^2&_\$__ /LJ_P <_P#U$/ %?>?_  9X?\HG+G_LXCXH_P#HK0J^
M#/\ @^$_Y(;_ ,$__P#LJ_QS_P#40\ 5]Y_\&>'_ "B<N?\ LXCXH_\ HK0J
M /Z0_P!IK_DV_P#: _[(I\4__4'UVO\ &W_X([?\I:OV$?\ LZOX=?\ J1K7
M^R1^TU_R;?\ M ?]D4^*?_J#Z[7^-O\ \$=O^4M7["/_ &=7\.O_ %(UH _V
ML&ZGZG^=%#=3]3_.B@#\/_\ @NA_P2'\-_\ !6G]E4^#="N=*\+?M)?"*>]\
M5? #QOJ\K6FE_P!JW<42:[X#\4W,%M=S_P#"+^,+.VBM3-'&!I.MV^DZPH-K
M:W-M/_F+7'PP_P""KG_!'G]H"^O="TC]H_\ 91^+NB2"QN/$O@3^WHO#?B[2
M;>]6XAM+W4-&34?!'Q$\'7MS:Q78T77HM:T*^,<3WFFNR!5_VI502-.IR,A!
MD=1D$Y^O YZ^A%8NN>%_#?B:&&U\1Z!H/B&TC VQ:]H^GZO"&RWW([^"=$(Y
M(*@8[=R #_&V_: _X+/?\%COVAO@[X\^#/Q__:=^+/C'X.>/]+&E>/?#6L_#
M#X=:#I6L:2;J"[%G>ZKHOPVT;4K*U-W;V\FVTU.S#-&BDE?EK]T/^#)#_D]3
M]L;_ +-=T3_U;'A:OZO/^#@WX<?#;P[_ ,$>/VWM4T/P'X$T._B^&5H+?4=.
M\*^']/NX)&\3:(JM;W5O813Q3'>40Q2+)\Y5#EB#_*%_P9($_P##:O[8HQP?
MV7-%.<'@CXL>%0!G&T9W$X)!.W@$!L '^D\5##!&1S^H([=.">:_DF_X.?O^
M")/Q+_X*)>!? '[4O[+.F0>(/VC?@)X=UCPOXC^&JM865Y\6_A9-<OK=O!H%
MW):QRW7CWP?JIOI-&TV_U%+;7-'U:_T^U,6IVNG0WG];.>2,=,<^N<]/IBF%
M#O!4X4EBP]2=F,=NJY)/;('7@ _QD_V!_P#@K]_P4B_X(ZZA\0OAA\%];M_#
MOA?Q%K5Q?>-_@'\=O -SKWA*Q\<V44&DR^*;/0[RX\.^*_"7BF.RLH]*U67P
M_K^D6/B"UMM/3Q1IVMR:%X>ETGE_VPOV_?\ @H]_P6W^-_PUTKXJ3ZO\7_%6
ME3MX7^#OP5^#W@=M'\%^%;WQ/<VB:E)H'A?21>W,VKZ]=6UHVL>*O%>KZQK!
ML[2TL9M9M]"TK3[*Q_UZ/C9^PS^QU^T5<G4/CI^S/\&/BCJ4I83:QXK\ :!?
MZS(SDL9)-66SBU!V:0_,TERQ.[YFQG.]\%OV0OV8/V<D'_"AOV?OA%\)Y&58
MWN_!'@;0M%U)T$9A0/J=O9)J#*(V(D!N,NI8$\MN /R>_P"#?'_@D]=_\$M_
MV,[?0_B-96T?[3'QOU&R\??'4PW]OJUEX>F@A:V\-> =+O+>-;<P^&M*?.I2
MP/<1W6N7>H31S&)8"O[WJ,'<=PW $J3P&. >",C''<CK@#N('"Y?!<YSMX!Y
M) &?3. 3^-24 ?Y,'_!U5X<\1ZM_P68^/5WIOA[7;^UB^'WP8W75GI&H75L%
M3P%IZL_GPV[Q&,,K(7#[0Z.I.Y6 _P!.G]@6.2']AG]C>*6.2&6+]ESX"I+#
M-&\4T4B_"[PNKQRQ2*LD;HP*LCJK*P((!!%>_:U\,OAOXDOY]5\1?#_P5KVI
MW4<<-SJ.M>%M#U2^N(8DV1137=]8SW$L<:?(B/(RHO"@"NPM;2UL8(+2RMX;
M2TM8(K:UM+:)(+:VMK=$B@M[>")4BAAAC58XHHU5(T 5%"C  +%?EU_P5_\
M^"=7AO\ X*=_L/\ Q0_9KU"\;2/&PC@\<?!KQ"UW);6VA_%;PO;74WAMM4.'
MCN-"U7SY]#U>*5<I::G/<12Q301.OZB_TJ-D& < X+-DG@9RQSZJ6QD#M]*
M/\5KX4?%W_@I#_P0E_;!\2:GX6MO$O[/?QT\*PWO@3QMX>\7^%[/Q#X&^(/A
M.>^L]1GT75-/UBTN-"\5^%M6ET^QU+2M;T6YM]5LBL>H:!K6DZ@IGC]J_;]_
MX+S_ /!2_P#X*F> -#_9_P#C!XM\.Z/\,'UFRU34_A+\ /!.I^#M,^).N6$\
M<N@'QQ$-:\3^)O%]IHU^$U'2/"TNK#PLFO1Z;K\V@7/B#1- U+2_]<SXO_LV
M?L__ +0FGQZ3\=/@S\,_BS8Q';!%X[\&Z)XD>W"JV4@N=1LYKB!%+ML6*50,
MDCYB"/)/A%_P3N_89^ VK#Q#\'_V3?@1X \01RM-%K6A_#SP^FJP3%A();;4
M+FSGN;5Q(%96MY$\O: A7' !_)G_ ,&L/_!"KXP?LV>,A_P4?_:WT#5?AYXX
MU'P5JOAC]G+X/:@\UCXBTG0_'%B;#Q3\3_B'IR-$^FWFI>'9)M \&^$M0$LB
MZ=K&K^(=9LK:^7PV]O\ W*J=B8?(P2N3U89^]QG YZ9.!WIR JOS'))R?R ^
M@SC.!P,X'2B10ZE3T. 3SG&X9P1T/'';.,\4 ?PU_P#![CI>IZU\%?\ @G_:
M:/INHZM=?\+5^.TGV;3;*YOIQ''X1^'RN_E6L4L@12PRQ7 )Z]A]X?\ !G]I
M^HZ5_P $I;NTU73K_2[H?M$?$]A;ZC9W-E,T;0Z&5E6*YBB<QMM90ZJ5+*P!
MR"!_3WK_ ('\(>*_L!\5>%/#7B=M,:[_ +.;Q#H>F:R=-%\L?VMK'^TK:Y-L
MUU]FM5N/)*><L$2OD1J1HZ%X:\/>%[(:;X9T+1O#VFB:6X_L_0]+LM)LC/,?
MWDWV6Q@@@\U_XY!'O<@;FXQ0!Y9^TPK/^SC\?D1'D=_@K\4E1(D:21W;P/KB
MHD<: O([,0JHH+,2%49(K_'2_P""0?A?Q/IO_!5W]A'4=0\->(;&P_X:M^'"
M_;+S1=3MK8,_B3Y4,TUM'&'.Q_E+ C8Y(PC8_P!I>:&*XBD@GCCFAFC>*:&5
M%DBEBD4I)%+&X9)(Y$)1T8%74E6!!(KSJ'X2?"K3IK/4;#X9?#ZQOM-NK>_T
M^\M?!OAVWN]/OH9"\-[9W,.G1S6UW [L\5Q"Z2QL69&#$T =^VS<V7P=QR/,
M(YSZ;N/I15<V^221'R2?F4LW//+9&3ZG R><"B@"U$#OFZC(3!_!AD?C^HK^
M=+]L?_@YO_X)X_L0_M)?%#]EGXP^'_V@+OXA_";5;/1?$UYX3\!:1J?AZ:\N
M],L]43^S+ZZ\3:?/=11VM]!NE-G&AE,B*69&Q_1&)W5G>.$2*RAV)<)A$W*>
M""20>",8R3M++\Q_D7_X*!_\&IG@+]OG]L'XW_M;>)?VS/&7@34/C#XEMM=_
MX0S2_A3H&I6?ABWLM&TW28]+BU-]>M)M3V"P:X:\N($FDDG=6+*B8 /YTO\
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MU-5'S[H=+5>Y_P!>O<Y/\/K1]HNO^?5?^_Z__$T 7J*H_:+K_GU7_O\ K_\
M$T?:+K_GU7_O^O\ \30!>HJC]HNO^?5?^_Z__$T?:+K_ )]5_P"_Z_\ Q- %
MZBJ/VBZ_Y]5_[_K_ /$T?:+K_GU7_O\ K_\ $T 7J*H_:+K_ )]5_P"_Z_\
MQ-'VBZ_Y]5_[_K_\30!>P!T&**H_:+K_ )]5_P"_Z_\ Q-'VBZ_Y]5_[_K_\
M30!>HJC]HNO^?5?^_P"O_P 31]HNO^?5?^_Z_P#Q- %ZBJ/VBZ_Y]5_[_K_\
M31]HNO\ GU7_ +_K_P#$T 7JAN/]2_\ P'_T):K_ &BZ_P"?5?\ O^O^%->6
MY="# BDLH4&;G.\8)PA&T\ \Y'7:>E $N\_W'_(?_%44T1HP!(R2 223DD\Y
&X.** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron_s33x10x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_s33x10x1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X &8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^Z?XP?&#X
M9? 'X9>-/C)\9/&>A_#WX8_#W1+KQ%XQ\8^(KI;/2=$TFTVAY[B4AGDEEE>*
MVM+6!)+J]NYH+2UBEN)HXV_FWL?^#N__ ().WGQ2M_AZ][\;[+P[/J@TT_%F
M\^'MLG@"!&F\L:A,J:Z_BI+ +^^:;_A'"ZQ<F,,"*Z#_ (.WM5U.R_X)":[I
M=A?W5C:>+/VD/@-X:UU;65HC?:-<:IKVIRV4VT@20M?:587)B<,C26T1*DJ,
M?3WQ3_X)/?\ !/O1O^"1_C[X!Z9^S+\-;'P3HG[-FO\ Q(T_4+?0+./QM%\2
M=#^&EWXGL/'\GC98QXEF\4+KMNMY/>RZDR3PO-ITD)TV5[0@'[._#;XE?#[X
MQ^!O#GQ,^%?C/PYX_P# 'B_38-7\,^+O"VJ6VKZ%K6G7*[HKFRO[1Y(9!U61
M"PEAD5XID25&0?F;_P %'O\ @M3^PE_P2_;2]#_:&^(-]JWQ-UFU34-.^#_P
MXL8/$WQ$.E2H'AU?4=+>]L++1-.NMRBQN-:U"Q^VY9[598XY'7\?/^#-3QCX
MEU[_ ()Q?%;PQK&K7FHZ-X%_:&US3O"]G=3RRQ:59:IH>FZE>VUHLCN+>":^
M>2X,,86-9'=@H+$U\G_LM?L^?![]KK_@ZL_X*-7W[2/@;1/B];_ ?3-)UOX:
M:%XVLX=>\.Z)K&B:%X$TO0=0ET34%N+"^?0+9I7TB"[@EM;6[E^V+!YR1,H!
M^_\ _P $W?\ @O!^P/\ \%/?%.J?#GX'>+/$W@[XKZ9IS:Q%\+_BQI%EX7\6
M:SI<,K1W=WX>^QZIJVDZX; B.2\M+#4Y[R"WF2X:W\A9'3]GF7:I8LJA0S,S
M'"J!DDDD8 '))/ ],"OX'_\ @X\_9O\ @_\ LB?\%+?^"6/[3O[,_A'3_@G\
M6/C!\:$M/B+J?PYB_P"$4T[Q+<^$/&OPUM],U>ZTK1S:V<.IW6F^(-1TG6IK
M6&!-:T]TCU&.YD#R/_5/_P %A_BOXU^$'_!*G]M+XG^ ]5FT3QIHW[/OB%M'
MUFTDE@NM+N]>CLM$N+^QFA>.6WO;6VU6YFLIHV#07*Q2*<H" #P']IW_ (.&
M_P#@E#^RG\0-8^%?CW]I?2_$GC[PW=&Q\2Z'\.-"UOQM#H%\H)DL=0US2;.3
M06OH#^[NK.SU*ZN+.4&&[2"8&,?HMXJ_;(_9S\ ?LP:5^V+\0_B;H'@'X ZS
M\/\ 0_B38>-/%MPND1W'A_Q+HD7B'0H;>SG/VN[US5+":*.PT.SBN-1O+IA;
M6UO+,<5_+E_P;:?\$;_V"_'_ /P3Z\ _M7_M"_ 3X?\ [2'QI^/&I>+M6UK6
MOC1X=T_Q]I'A[2+3Q!>:?IVD^'_#_B.&^TBUN'ALQ>ZIK4MI-JU[?7-P1>);
M>7 ,G_@[YT/2?#_[+?\ P3G^ 'A>PM?"7PEUG]I[2_"TO@KPQ!%HNA66@>'?
M"=IH'A_2].TRP2"RL['0],U>]MM*M(8%M[)63[/&GEKM /KWP/\ \'<7_!)_
MQI\6K#X9SZC\:/".CZCK=IHEI\5?%/@.TL_AZ&N[J*T74;J>TU^]\066F1O,
MLL]U>:#"(+=7E=0JFOZ</#^O:%XMT/2?$_A?6=+\0^'-?T^UU;0]=T6]M]2T
MG5]+OHDGL]0TZ_LWFM;NSNH9$E@N+>1XI(V5D8J<U^ __!1K_@E?^P%H/_!&
MWX\_#;P[^S'\,?#^B_L^_LN_$WXF_"35](\.6%IXQ\)^/O"7P]U;Q18^*HO&
M$<0\0W^KZGJ]H)?$-QJ6HW?]N1W%S#J"S(ZA.8_X-5O&WB?QA_P1Z^"EKXDU
M>\U=/"7BSXB>&-"DOKB6YFL="M?%%[=VFFI-.\D@M;.2\F2TA#>7;P%((52)
M%50#[E_X*/?\%COV'?\ @EYI.F#]H_XAW%U\0]>M4O\ PY\&_ -G%XD^)FLZ
M4TZV\FL+H[W5C9:5I,<A(2^US4M,ANBDB69N'BE5/$_^"<__  <!_P#!/;_@
MI9X[/PD^#WBWQ;X!^,$\&H7NB_#'XNZ':^&O$/B>PTN*.>^N?#UWINJ:WH6I
M2PQ2^<=/CU8:DT44TB6C)$YK^<GX"_##P)^UA_P=Z_M8Z7^T-X:TKXK^'_@W
M:^,=6\!>%O&=G!K_ (9TF\\'> _!MAX8+:'JB7.GW$.BS:S?:Q96TT#P0ZS(
MFH+%YT:D</\ \'5WP0^&W[*7[=7_  3R_:B_9P\-Z;\%_B[XPUE(_$NL_#JR
MM?"EKJ^H> ?&?AR;PUKUQ8:+%96JZY!;:K=:7>W\<22:GIJVMM?M.MK$5 /]
M"Z/H?K_0=^]%0V;M);0.QRSPQ,Q]6**3W]?RHH _F _X.Z/^42L/_9UWP _]
M&^+Z_<#XS?\ */OXJ?\ 9G?C;_U2VI5^'_\ P=T?\HE8?^SKO@!G_O[XOK]P
M/C-_RC[^*G_9G?C;_P!4OJ5 '\U__!EY_P F _M!?]G)7G_J*Z97)_\ !-:Z
MM['_ (.D?^"PE[=RK#:V?A%KJYF<X2&WM['P1+-*Q[+'&C.V.@4FNL_X,O/^
M3 ?V@_\ LY*\_P#45TRN1_X)LV=MJ/\ P='?\%A]/O(Q-9WW@^2SNH6)"RVU
MS8>"8)XR00P#Q2.I((.#D'(% 'Q'_P '&?[<O[)_[8G[6G_!)^P_9H^-W@SX
MO7GPU_: UFT\=6_A.^:\?PW<:EX^^%5MI\6H;HXS&]W-I.HI$ "&^RL<G(K^
MIO\ X+J_\H:?VY/^S?I/_3IX?KSY?^"!_P#P1;^'?CKPYXYN/V8/AOX7\:P^
M*[7Q5X;O]6\?^*-.N9_$UAJL.KVUWIMGJ'BR*&]FM]3^SS"VA@FCW-'$T15@
MI],_X+R1QP_\$=_V\8H@%BB^!5]'$%.5$::WH2Q@'N @ ![]<F@#QO\ X-J/
M^4-W[)?_ &"_%W_J6ZM7Y5_\'AW_ "3_ /X)G_\ 9WTW_ILT"OU4_P"#:C_E
M#=^R7_V"_%W_ *ENK5^5?_!X=_R3_P#X)H?]G?3?^FS0* /Z(_\ @I;_ ,HK
MOVWO^S(OCK_ZIOQ#7Y5?\&F'_*(/X<_]E*^)?_I^>OU5_P""EO\ RBN_;>_[
M,B^.O_JF_$-?E5_P:8?\HA/AS_V4KXE_^GUZ /RJ_P""?O\ RM__ /!0/_L!
M?%?_ -17X<UA_P#!YC_R6/\ X)F_]C'XP_\ 4K\$UN?\$_?^5O\ _P""@?\
MV OBO_ZBOPYK#_X/,?\ DL?_  3-_P"QC\8?^I7X)H _O,L?^/.V_P"N$/\
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M6T6YF*(0#Y!_X,N6W?\ !/[]H!R,%OVD+ML=^?">EMCZC..QR*^+OVP_B_\
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M!.2$AA1(T!/)VJ,GFK#*K*RLH96!5E8 JRD8*L#D$$$@@C!'!H _S[OVD/\
M@Z1\2?M;_L)ZO^QQ\+?V(/B.W[8_[1?@+Q'^SOX\\+DZI?>#_",'CK1;CP._
MB#PE'%I">(-=U35X=41M(T/5;728=(O)7_M+4;J"V0W/]0/_  0:_8D^)G[
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# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>geron_s33x10x2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_s33x10x2.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !! -P# 2(  A$! Q$!_\0
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MP/A9X(O;E7>UM?&+^)/"]Q=*AVDV\.N:!8/<$G/EK$',H5FB#JC$<NW_  7
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MRR,*CP]"K2E4:O'VMU![7]^UTM6U:]XJ*>K7^LWX2_X*_P#_  35\?WEQ8>
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M;RPE:M6A)U53BU:W)&:76^DI-[K36ZZW(9N=HYYW#  R3P /IDGCO_/\B/\
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MM!>%5OG>RDGNI+Q;JV:'^B@ 'N20<$C(Y^@K^5']AOX!_M@?\%!_^"E.A?\
M!5#]LK]GC4/V5_AU\!?AP_P\_9?^#OB2\,WC35-4U0:R-=\::]I4X^U:<LMG
MKUUY%Q<P0M,)HK:TW+;W+#^J\#'<^^,<GU.<\_C7G<;TL)',L!+#4,NPV8O(
MLLI9]3RK$5*V"><T8U%B)TY.K7I*I.E*B\0Z$W3==S2=XL>&E)^U<H3AS3<H
M\ZU<97VVNEWTWV*URQ0*PQD;L#\B/Y<CCKP:_(O_ (*VLK^&_P!B5BQW-_P4
M#_9BXQQD^)+DX&3G VY)ZY)ZBOUJU"6-'@5U8AED;.2L85#&/G<$*"S2*B*2
M'9F^0$!B/Y.O^#C[_@I5\.OV:O$_[&GP9TB[_M[XE>$OVA_AC^TEXVT33Y],
MNF\.> / &KW$ULFI*]U]IMM8UYVDDT2PN(DCO+"$SNZQ21.RX!R['9UQ5@\!
ME="OB,7_ +9+EHX>M-P@LLQ7,^:$9J2;J03:22<TKMZ*<QJTZ.#4ER\[JTU)
M-J]G42=[O90BW=;)WM?4_J_='DA9%*AOM$S!L#<CI<921,YY5D4D'Y2 037^
M<C_P=8?\$_9_@7^U7HG[:W@O23_PK_\ ::DM]*\=?9H&^R>'_B?X>T:VTXRM
MY$,:6T7C+28%N)'=F#7EI=2H\<V*_P!!SX._&GX:?'?X:^$/BY\)O$^C^-O
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M8OF246K<W*^9-NR5K:VNMS_9-_X)C+G_ ()Y?L5'H5_9P^$^,@YQ_P (=IH
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M:+X.\+:!83ZCK&N^([ZWTK3;&SMHI)I9IKJ[>*(!(XW8INWXP0A#*3_F;_\
M!P+_ ,%HM,_X*0?$#0O@3\!9-1MOV7/@YXAGU^VURYC-K>_%'QX8+G34\3S6
MUMYD9\+:%I\MQ'X:CF*3F[OKJYFB&%(ZO"GP_P U\0^,LGRO#83$O+(XZC+,
ML3*A56'4*=6->5.=:,%!>TC1=.-JJ]V?,Y*R,\VQ\,%@YRBN>K*]G!J3@_LW
MBG=>\TOA;;T:W/[(?^#<;Q)K_C3_ ()/? OQMXHNO[0\2>*?&WQN\1:]?2H3
M)=ZUK7Q@\77]_> N[N&:2Y\B(,[^7:Q)%EAEA^[;'''&0" >^<X],=2.>/<>
MGX'_ /!LZBM_P1X_9I&XS,VN_&*0,BL8_,7XH>*D&25"@'&] <,&VG *MM_>
M\J20?;/Y,/U.#]< >F?$\0\-2PO'7%6#C&/LL%Q+FN'2@H^S@L+BZM&-G&Z?
M*Z3LUUWN;82I*I@,%*;?/52E5<OM<T6TG9+:SOHDWNF?YZW_  =A_L!1?"_X
MT>"OV[_ASH;Q^%/C2;?P-\9391C[/:?$W2[7S?#>KRA8-MNWB/1@8);F:9C<
MWUM&K'S0@/C_ /P;$_MVZG^RWXS_ &X_!7B>1;_X1Z7^RYXA_:070 K'4+SX
MH_#WQQ\,_A[H'A[0[1I09+GQ?8_$G[ ;>*":YU&ZL+.6-PD.Q?[E?^"E_P"Q
MUI7[=_[$'QU_9DOVMX-7\<^%VO/!NIW*D1Z)X\\.7,6O^$]25H8WFC$>KV$$
M-P\<;2M;S3Q[3'*V/\^'_@W?_9 U?XE_\%=](^&OQ%BN]+'[,/AWXB?$SXI>
M#[EKRT.MWGPW\2^&/!NF>']5M6B_TW2--^)/BCPOKL%G=*D4@TRRFF/FB)&_
MHW@WB7*^+?H_\8\-Y]B8+%\*8C#8^A.:3K5\![N(PE-*K53YG5PU/ PY4FW6
M3;<FD?,XS"_4^),#7P\6OK4GSN,6XJ\9WBW:44G:_225DFHO7_0J_P""??P4
M\1?!KX!:3>_$&\DU3XM_&KQ!KWQZ^,&I74C37*^._B=-'K5SH<3R*DL>G^%M
M/_LWPSI=K*)186FEFVMW\G:$^Z:A5'#*2$50%!54 .U5PBY&1\C?,"IVL&XP
M.!-7\F8O$3Q>*K8FI93K2<VDDHJ[?+%)))*$%"$8I)14;):N_P!H[:222<OB
M5VW=:)OL[;]'H_)2G[GX+_2OP5_X.+!_QK_T ]O^&LOV3>O8_P#"Z/#9'!_'
M/T'2OWEK\&_^#BUDC_8!\,O(RQQQ_M;?LHRRR2,(XUBB^,WAF21F=R%P$5OE
MZGH!UKW.$4Y<3Y)&*BW+&RC:6B=\-BK+=6O+3=''CHN6$K)1<FXJR7^*-_PN
M?N'HBJVCZ$&*G_B1Z4R=1AFTV%>>Q(5#MQCYV7T ,>KWEOI5K+>:M?V&FV5L
ML<MUJ6HS6%E:6=O$\9=[N[OU:W@0>8-[R^62[JL<BM@U\L_M?_'G5_V9/V+O
MC-^T)X<\.S>*]<^$WP4U/QCHF@Q0S3C4]4TSP[$^G+-! PFDL8+MX[B^(5PM
MO%*?+S@C^/'Q_P#\%7_VJ/@IX./P<_;T^(?[.?\ P4B^''[>WP6G@^'7PM_9
M@\0Z9X?\8^ ?B!XVFTI-$\+>,M1":>8/"URNL_V5=8O7UZWNX5>VM6C!)[>'
MN LXXOQ.)KY;.DZV&JUL)'"/$2A4Q5*-65?%2HT^7EF\)2;Q%7VM?#>Y!QIR
MJ-.!-;&PPGL>>/M.=;6;:BTE3>FUV]%9[.^[9_<]HOC/PEJ-_'8:-XDT#5;R
MZTP:I9Z9I.N:/JU]=Z4US-''J]I%:WCW5YIK,DMN+Q6FM4N8_*0P ,']+_IQ
M7^?Y_P $F_V8?B+_ ,$PO^"K/[*7@;]J7PKI]]X[_;,^!7CE?A7X)\->./$'
MB";]ER"TUK7?$-MX)UQKZ[:WU?1[O0-.\J]>!9[#3]5N6CC#R&5A_H KG&#V
M/UQTX_#_ #Q7/Q;D&"X=S.&"R[-:6=X6>&IU8X^C3=*G.KS2I8BE"$IR?)2K
M4YQC4YG&JE[2'NR3-:&)EB.=.#C[.R5VM5)RZK9JVJ>NM]-E\P?M,_L]^,_C
M]I_A?3_"'[27QM_9T.@OKG]I7WP6O_"NGW_B:/5TTN*WCU>?Q-X<\0;1HPL;
MF33FL!:2(^HWIE:8F#ROPH^*G_!K1^QM\</B!XB^+'QB^/\ ^UK\2OB7XNEM
M[CQ)XT\6_$?2-3US5;NTL(=-M;BYNY?#H0_9+.".VLH8HX[>T@40VT2*JFOZ
M>*0\_P"3_0BLL@XOXEX5K1Q/#F;XC)\3"$X1Q."CAX8A1J.3G!UIT)U'%N3]
MV4G%:))))(KX:EB(\M9.<;J2BW>*:5DTK=C\!OV;O^"!?P]_8]ANK3]F+]MO
M]MOX/:??F234-$T#XC^'-0\,7<\IB:>XD\,:[X5U/18I)Y(A)(UO8QL7,A##
M>0/V\\(^$]7\,>&/#_A[4O%>L^,[[2-.AL[[Q5XA6P37]<N84"G5=1.E6FFZ
M8NHS,1YQM+"ULS'&%BM(RP5>]QSGC\N<>F<TO^?2O,S'-LRS?$U,9F>*GCL7
M6G*I4Q->G0]M4J3E*;J5)PI0<Y\TFTY)\NEM-#:G"-*#IPBHP=FX)*UU'E5O
ME>_=MMGP%\'O^"<O[.'P3_:[^//[;'@?PI-IOQM_:'TC0M,\<ZA)>>?I%I+I
M/G-?:GX>T^5)%TK4O$;-:'6Y;=ECNQIUF6C5ED,WT5\:_A/XG^*G@>?PGX4^
M,/Q#^"VKS:G8:B/'/PVDT&/Q-#;V<K33Z5&WB'2M9TP:?J /EW(-D9T!WPS1
M98'W+!SUS_G\OTI:YJV+Q>)Q&'Q>)Q%3$8G"T88>C.ORU5&E22C3@Z<U*E*,
M8I)*4&MW:\I-RJ452E15U"3;E:RD[MM^\HI]7M9[:NRM_/U^TY_P0"^&W[:/
MV$?M2_MH?MI?&&UT>4R:#HFO?$#PG8^&=(=7$L=Q:^'-$\(Z;IDEUN5%^UW<
M<UT-BGS. 1\FG_@T2_X)U,\<G_"Q/VE=T#0M;AO'6B!;=;=56W6,?\(__P L
M-F8V<R$%FR37]6]'^?\ //\ A7V>5^)W'^2X2& RGB?,,NP,,1'$PP>$6%HX
M>%>,>55(4HX91BTND?=U>FK.9Y?A'O23>C<GK*375RES2NWJVFC^>S]F[_@W
MO^%7['.H7^J_LM?MF_MH_!B;6;J.[U^P\.?$+PU=:'KKQ[%4ZIH6K>&+S2)Y
M%6-4-P+19GB01,Y"@U^R7P-^#WC7X4^$[[PWXU^.GQ)^.NHW=]/=0^+?B1'X
M5AUFQMYK=8?[-M4\+Z+HMD]FCYGC^UVEQ,LXD(E$;HB?0-%?.YMQ#G6?5ZF*
MSG&_7\35;E4Q-7#8.&(J2<Y3O.M0P]*I)N<G*\I-ZV;:T.B%"E3=X1<=+64I
MV^YR:_3;31'XU?M+_P#!(>?]KSPMJ_@#X[_MU_MC>)/AQK.HZM>WO@'1/%?@
MCP;X=GMM0NYY[31]0'A;P=I5_JVD:1;W#V%I9ZE=W'FVXW7;SR,&7\W%_P"#
M0S_@G*B*!\1?VD,",1^5'XVT..!5)RZ10KX?5(T8D[0#E,C&=H!_JW(S[?3B
MEKU,HX]XSR##O#9+Q!C<LHRNYPP<,)14V]&YN&'BYMK=MN_4QK8'"UVW6HJI
M?^>5222:2TBYM*R5K))=7=W9^(_[+G_!%S1_V*? 5_\ "[]EO]M#]J3X2^ M
M3UF7Q#>^';.?X9>)(9-:N8DM[F^%QXD\#:A=Q&>".&)XHI5BQ$) HD9W;Z7B
M_8?^/*9#?\%&OVL2O^Q8_!96)!&,L?AH2!CD[<'L&QD'](<45Y&)SW-\;BL3
MC<9BH8K%XNI[7$8BOA,#.I5FDDI2OAK7MUW?6Y4<)0A%0A&4(1348JI4LKWN
MDG-I+T2\[GX$?M,_\$$O ?[8\%O8?M+?MN?MN?%;2K25);?0-9^)'AFP\*0[
M=S!!X7T/PIIFD2 LVYGN+69RX#A@2:^/O^(0W_@G*P ?XA?M)'8H6(#QUHH$
M3@ "1<>'58A0JHD.?(CR2D:KN!_JXHKWLL\1N/,DPZPF3\3YCEF'7-:E@5A,
M/!*3=XVI86%XVE):R>C=M6S&>68*I+GG04I:M\TIV;:M=^]=O6]]-=3XW_8?
M_8Q^'?[!O[.G@3]F;X3:IXGUKP+X!O?$U[HNJ>+[^WU+Q#YOB?6=1U[4#=W4
M,,%O*#>:C/%&L,$ 6-_E"#('U\(&XR?;/'J??H,YQ]1[FU1CZ_R_ES_^NOD<
M7B,1CL1BL7C*LJ^*QV(JXK%UY<JG6Q%:?/5JRY4H\TY:NT4FVW:[;.Q4XJ%.
MFDE"DK0BNWO))MZZ<SV:V76]ZC6H*D%B>&QCY=N002/FP,J2IQ@X8D$&OS#^
M!_\ P2[^$OP+_P""CO[2'_!0SP?=+8>)_P!H;X2Z3\-]2\)VMK)#:Z1J$OB'
MP]XC\<>)(YUO)+>:;Q??^"_!TT\"6D)M[C299M\C7<N?U'I,=.>GIP/R]NU;
M8?'8O"4<=A\/6G2HYGA98/'0B]*^&E5I5G3DGM:K0I3C*-IQ<;1DE*28Z<9.
MFY*_LG>%TM)6<>:]N:]I-6YN75MINS*XM\<;R>2<D$D9).,EN@X '8 "E\C_
M &__ !W_ .RJQ17&DHI);)67?YO=ONVRROY'^W_X[_\ 7KY*_;/_ &.?A[^V
M[\'[+X,?$[6?%FC>&K#XB?#WXF07O@W48-+U@:_\-_$EIXGT./[3<6]U&;.6
M^LXTO(C$1+"2O%?7M%;4*];#5Z6(P]25*M1GSTZD5&\96E&Z335[2:32NK[D
MSBIQ<)7M+1VTT_R[G$ZUX*T3Q+X7U#P=XCTNTUWP[K&B3^'-8TG4H8KFQU71
MKRR.FWUC?VTF8I(;FS!21%5!^]8###</Q5\1_P#!N/\ \$JKKP#\1O!_@/\
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=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
